News | April 28, 2026
Jagsonpal Pharma profit surges 31% in Q4
Rs. 40 cr buyback, 200% dividend announced
Rs. 40 cr buyback, 200% dividend announced
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Subscribe To Our Newsletter & Stay Updated
